Publication | Closed Access

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

InflammationAnti-inflammatoryImmunologyGastroenterologyPathologyPediatric PatientsPediatric GastroenterologyAutoimmunityHemophagocytic LymphohistiocytosisUlcerative ColitisMedicineRheumatoid ArthritisSystemic Juvenile Idiopathic Arthritis